Article Versions Notes

Bahlool AZ, Fattah S, O’Sullivan A, Cavanagh B, MacLoughlin R, Keane J, O’Sullivan MP, Cryan S-A. Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis. Pharmaceutics. 2022; 14(8):1745. https://doi.org/10.3390/pharmaceutics14081745

Bahlool, Ahmad Z., Sarinj Fattah, Andrew O’Sullivan, Brenton Cavanagh, Ronan MacLoughlin, Joseph Keane, Mary P. O’Sullivan, and Sally-Ann Cryan. 2022. "Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis" Pharmaceutics 14, no. 8: 1745. https://doi.org/10.3390/pharmaceutics14081745

Bahlool, A. Z., Fattah, S., O’Sullivan, A., Cavanagh, B., MacLoughlin, R., Keane, J., O’Sullivan, M. P., & Cryan, S.-A. (2022). Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis. Pharmaceutics, 14(8), 1745. https://doi.org/10.3390/pharmaceutics14081745